Literature DB >> 24622628

Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK.

A Potts1, G J Williams2, J A Olson3, K G J Pollock1, H Murdoch1, J C Cameron1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24622628      PMCID： PMC3965826          DOI： 10.1038/eye.2013.303

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  11 in total

1.  Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

Authors:  A J van Hoek; N Gay; A Melegaro; W Opstelten; W J Edmunds
Journal:  Vaccine       Date:  2009-01-09       Impact factor: 3.641

2.  Factors affecting visual outcome in herpes zoster ophthalmicus: a prospective study.

Authors:  Suneetha Nithyanandam; John Stephen; Mary Joseph; Supriya Dabir
Journal:  Clin Exp Ophthalmol       Date:  2010-12       Impact factor: 4.207

3.  Recovery of ocular motor cranial nerve palsy after herpes zoster ophthalmicus.

Authors:  Manpreet S Chhabra; Karl C Golnik
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

Review 4.  Ophthalmic herpes zoster.

Authors:  R J Marsh; M Cooper
Journal:  Eye (Lond)       Date:  1993       Impact factor: 3.775

5.  Population-based study of herpes zoster and its sequelae.

Authors:  M W Ragozzino; L J Melton; L T Kurland; C P Chu; H O Perry
Journal:  Medicine (Baltimore)       Date:  1982-09       Impact factor: 1.889

6.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

7.  Central nervous system involvement after herpes zoster ophthalmicus.

Authors:  Birgitte Haargaard; Henrik Lund-Andersen; Dan Milea
Journal:  Acta Ophthalmol       Date:  2008-01-24       Impact factor: 3.761

Review 8.  Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.

Authors:  Thomas J Liesegang
Journal:  Ophthalmology       Date:  2008-02       Impact factor: 12.079

9.  Prognostic value of Hutchinson's sign in acute herpes zoster ophthalmicus.

Authors:  Michel J W Zaal; Hennie J Völker-Dieben; Joe D'Amaro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-11       Impact factor: 3.535

10.  Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Authors:  Sinéad M Langan; Liam Smeeth; David J Margolis; Sara L Thomas
Journal:  PLoS Med       Date:  2013-04-09       Impact factor: 11.069
View more
  2 in total

1.  Response to Dr Clearkin.

Authors:  G Williams; J A Olson
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775

2.  Comment on 'Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK'.

Authors:  L Clearkin
Journal:  Eye (Lond)       Date:  2014-09-05       Impact factor: 3.775
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.